STA2R , which is a panel of genetic tests, provides clinicians with new information to select personalized antipsychotic and antidepressant drug.
The test also helps clinicians to identify the patients for whom risperidone, the current antidepression treatment is contraindicated.
STA2R combines the propriety SULT4A1-1 genetic signature with four other gene tests.
SureGene president Bill Massey said STA2R represents a change to the treatment of schizophrenia and bipolar disorder.
”For the first time, physicians will have a test that can help them prioritize the treatment choices for their patients," Massey added.
STA2R requires cheek swab in the clinician’s office, which are then placed in the pre-paid shipping container to be delivered to PGXL Laboratories, Louisville, US, and within a few days, the clinician receives a secure report.
SureGene discovered and patented the SULT4A1 genetic signature while PGXL Laboratories independently developed the STA2R test.